Litcius/Paper detail

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models

Giulietta Maruggi, Corey P. Mallett, Jason W. Westerbeck, Tiffany Chen, Giuseppe Lofano, Kristian Friedrich, Lin Qu, Jennifer Sun, Josie McAuliffe, Amey P. Kanitkar, Kathryn T. Arrildt, Kai-Fen Wang, Ian McBee, Deborah McCoy, Rebecca S. Terry, Alison Rowles, Maia Araujo Abrahim, Michael A. Ringenberg, Malcolm J. Gains, Catherine Spickler, Xuping Xie, Jing Zou, Pei‐Yong Shi, Taru S. Dutt, Marcela Henao‐Tamayo, Izabela Ragan, Richard A. Bowen, Russell Johnson, Sandra Nuti, Kate Luisi, Jeffrey B. Ulmer, Ann‐Muriel Steff, Rashmi Jalah, Sylvie Bertholet, Alan H. Stokes, Dong Yü

2022Molecular Therapy86 citationsDOIOpen Access PDF

Topics & Concepts

ImmunityVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)BiologyMessenger RNA2019-20 coronavirus outbreakImmunologyMedicineImmune systemGeneInfectious disease (medical specialty)GeneticsInternal medicineOutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyImmunotherapy and Immune Responses
A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models | Litcius